🔥Telegram İfşa

"In clinical practice, type 1 diabetes classification in adults is difficult and misclassification is common" Having been diagnosed ad type 2, then LADA and finally as T1D, I found this lifts the veil a bit on how tricky it can be! #GBDoc

Reported changes in characteristics of older-onset #T1D may be explained by challenges in classification & the inadvertent study of those with & without autoimmune aetiology diabetes. ExeterDiabetes Exeter Med School NIHR Exeter Biomedical Research Centre (BRC) Angus Jones Nicholas John Meyrick Thomas tinyurl.com/3y2bzez3 🔓

📊 OUT NOW Communications Medicine - Young et al. review the evidence on #T2D treatment effect heterogeneity with #GLP1 receptor agonists and #SGLT2 inhibitors | Katie Young Adem yesuf Angus Jones John Dennis Ewan Pearson Exeter Med School UoD Medicine #PMDI nature.com/articles/s4385…

My PhD Studenship advert is live! If you know anyone who is committed, curious and driven to learn: please forward the link. The successful candidate will be joining an amazing community of scientists and innovators 🔬👩‍💻#diabetesresearch #spatialbiology lnkd.in/eA_5KGaK

@youngdiab - if u r an SpR, or nurse/ dietitian/ podiatrist interested in research or have an idea, get in touch with any of the committee and we r happy to direct you to an appropriate supervisor and help your application DSNforumUK BDA Diabetes SG 💙 Royal College of Podiatry

One in six billion podcast 𝐄𝐩𝐢𝐬𝐨𝐝𝐞 𝐭𝐰𝐨: 𝐀𝐧𝐧𝐚 𝐆𝐥𝐨𝐲𝐧 - 𝐭𝐡𝐞 𝐠𝐞𝐧𝐞 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐯𝐞 available now! The story of neonatal diabetes continues as we hear about Anna Gloyn and her remarkable science that led to gene identification in neonatal diabetes.

Precision medicine in type 2 diabetes - our new Exeter Med School paper in Diabetologia developing a treatment selection model for GLP1-RA & SGLT2i treatments using Bayesian Causal Forests link.springer.com/article/10.100… Web calc using routine clinical features: pm-cardoso.shinyapps.io/SGLT2_GLP1_cal…

Precision medicine in #type2diabetes: Cardoso et al develop a new approach for phenotype-based targeting of SGLT2-inhibitors and GLP1-receptor agonists tinyurl.com/bp89t8aa🔓 Exeter Med School John Dennis Angus Jones

In light of his career in diabetes research spanning 45 years, Professor Noel Morgan from the University of Exeter has been honoured with two prestigious international awards, celebrating scientists who’ve made significant contributions to the field.👉🏽 orlo.uk/Veqap

Save the dates! 📆✅ The ABCD Conference will be held on the 4th and 5th September 2024 at the Marriott Delta Hotel Bristol City Centre. The Diabetes Technology Network UK DTN-UK Meeting will precede the ABCD Conference on the 4th of September.

One of my highlights 2day at #DUKPC24 was listening to Craig Beall_Lab🏴󠁧󠁢󠁳󠁣󠁴󠁿 and Melanie share insights into growing as an early career researcher, chaired by none other than Shivani Misra. Thank you Diabetes UK.

Sarah Richardson ExeterDiabetes Diabetes UK Research University of Exeter Faculty of Health & Life Sci University of Exeter Thanks so much for tweeting this, Sarah Richardson, in relation to our talks. Couldn't agree more!

Great to see JC Katte presenting about early-onset diabetes phenotypes in Africa. A great speaker 🔈 Congrats Jean-Claude ☺️

Job opportunity in Exeter to work with Dr Martin Eichmann in the Islet Biology Exeter ExeterDiabetes teams looking at beta cell reactive TCRs using RNAseq. Apply 👇🏻 jobs.exeter.ac.uk/hrpr_webrecrui…

For the past 3 days, I have been attending the NIHR Global Health ExeterDiabetes Steering Committee meeting on Improving outcomes for people with T2D in Sub-Saharan #Africa, held at the UVRI/MRC LSHTM Uganda Research Unit, Entebbe, Uganda. Wonderful chairing from Amanda I Adler

Final day in Uganda 🇺🇬 and as well as progressing diabetes PhD projects we heard about the substantial inequalities in treatment across the 🌎 (the paler the colour the lower % of treatment coverage) - so much work to be done ! Angus Jones @athattersley Exeter Med School Research & Development at the Royal Devon

5-drug precision prescribing for people with type 2 diabetes is here - The Lancet our @ExeterMedmodel for optimising glucose lowering therapy using low-cost routine clinical features Paper: thelancet.com/journals/lance… Web calc: diabetesgenes.org/t2-treatment/